The essentials
Paramount shareholders approved the merger with global regulators clearing waiting periods ahead of Q3 2026 closing.
Paramount shareholders approved the Warner Bros. merger, advancing the transaction despite ongoing antitrust challenges across multiple jurisdictions. The approval represents a critical milestone as the deal moves toward its scheduled closing by the end of third quarter 2026.
Multiple countries and regions have cleared or expired waiting periods for the merger, accelerating the regulatory pathway. This global progress contrasts with active legal opposition—twelve state attorneys general continue their antitrust lawsuit, and the European Commission remains in its extended Phase 1 review. The shareholder vote signals company commitment to the timeline, though Paramount faces $650 million quarterly payment obligations if closure extends past September 30, adding financial pressure to regulatory uncertainty.
The deal's trajectory now hinges on resolving remaining regional reviews and state-level litigation while maintaining momentum toward the third-quarter deadline.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Shareholder approval and global clearances accelerate path to Q3 2026
Paramount shareholder approval and multiple countries clearing regulatory waiting periods demonstrate tangible progress on the merger timeline. The scheduled Q3 2026 closing date now benefits from both corporate and international regulatory momentum. However, remaining European Commission review and state antitrust litigation could still create delays, making each regulatory clearance a critical step toward the September 30 deadline when financial penalties activate.
Shareholder vote advances deal despite persistent legal and regulatory hurdles
While shareholders approved the merger and multiple jurisdictions cleared waiting periods, substantial obstacles remain. Twelve state attorneys general continue antitrust litigation, and the European Commission extends its Phase 1 investigation, signaling regulatory skepticism. The shareholder approval proceeds independently of these legal challenges, which could still block or delay the transaction even as the company races to meet its financial commitments tied to the September 30 closing deadline.